BACKGROUND: The overall incidence of myeloid malignancies is 8.6 per 100 000 persons. Allogeneic stem-cell transplantation (SCT) is a major therapeutic option despite its risks, which include graft-versus-host disease (GvHD) and infection. In Germany, about 1600 patients with myeloid malignancies undergo SCT each year. The indications for SCT have changed since the introduction of tyrosine kinase inhibitors (TKI) and improved methods of SCT. METHODS: This article is based on relevant guidelines from Germany and abroad and on a selective review of the literature from 2010 onward. RESULTS: The individual indication for SCT is based on the risk of disease progression, accompanying illnesses, the probability that SCT will result in cure, and the risk of complications. There is good evidence favoring allogeneic SCT in the following situations affecting 20% to 50% of patients with the respective disease: advanced chronic myeloid leukemia (CML) or CML that does not respond to TKI, Philadelphia chromosome-negative myeloproliferative neoplasm (Ph- MPN) or myelodysplastic syndrome (MDS) with a high risk of progression, and acute myeloid leukemia (AML) that has high-risk cytogenetic features or is recurrent. Good evidence is accumulating in favor of allogeneic SCT in older patients as well. CONCLUSION: The prognosis of patients with myeloid neoplasm can now be assessed more accurately than before. This facilitates well-founded clinical decision-making about SCT, which is the only potentially curative treatment for most patients with myeloid neoplasm. Patients up to about age 75 should be referred to a transplantation center for consultation at an early stage of their disease so that the treatment options can be evaluated. A major goal of current research is to reduce toxicity with innovative forms of treatment.
BACKGROUND: The overall incidence of myeloid malignancies is 8.6 per 100 000 persons. Allogeneic stem-cell transplantation (SCT) is a major therapeutic option despite its risks, which include graft-versus-host disease (GvHD) and infection. In Germany, about 1600 patients with myeloid malignancies undergo SCT each year. The indications for SCT have changed since the introduction of tyrosine kinase inhibitors (TKI) and improved methods of SCT. METHODS: This article is based on relevant guidelines from Germany and abroad and on a selective review of the literature from 2010 onward. RESULTS: The individual indication for SCT is based on the risk of disease progression, accompanying illnesses, the probability that SCT will result in cure, and the risk of complications. There is good evidence favoring allogeneic SCT in the following situations affecting 20% to 50% of patients with the respective disease: advanced chronic myeloid leukemia (CML) or CML that does not respond to TKI, Philadelphia chromosome-negative myeloproliferative neoplasm (Ph- MPN) or myelodysplastic syndrome (MDS) with a high risk of progression, and acute myeloid leukemia (AML) that has high-risk cytogenetic features or is recurrent. Good evidence is accumulating in favor of allogeneic SCT in older patients as well. CONCLUSION: The prognosis of patients with myeloid neoplasm can now be assessed more accurately than before. This facilitates well-founded clinical decision-making about SCT, which is the only potentially curative treatment for most patients with myeloid neoplasm. Patients up to about age 75 should be referred to a transplantation center for consultation at an early stage of their disease so that the treatment options can be evaluated. A major goal of current research is to reduce toxicity with innovative forms of treatment.
Authors: Alice Fabarius; Armin Leitner; Andreas Hochhaus; Martin C Müller; Benjamin Hanfstein; Claudia Haferlach; Gudrun Göhring; Brigitte Schlegelberger; Martine Jotterand; Andreas Reiter; Susanne Jung-Munkwitz; Ulrike Proetel; Juliana Schwaab; Wolf-Karsten Hofmann; Jörg Schubert; Hermann Einsele; Anthony D Ho; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Michael Lauseker; Markus Pfirrmann; Joerg Hasford; Susanne Saussele; Rüdiger Hehlmann Journal: Blood Date: 2011-10-28 Impact factor: 22.113
Authors: Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase Journal: Blood Date: 2012-06-27 Impact factor: 22.113
Authors: Bart L Scott; Ted A Gooley; Mohamed L Sorror; Andrew R Rezvani; Michael L Linenberger; Jonathan Grim; Brenda M Sandmaier; David Myerson; Thomas R Chauncey; Rainer Storb; Veronika Buxhofer-Ausch; Jerald P Radich; Frederick R Appelbaum; H Joachim Deeg Journal: Blood Date: 2012-01-10 Impact factor: 22.113
Authors: Jan J Cornelissen; Dimitri Breems; Wim L J van Putten; Alois A Gratwohl; Jakob R Passweg; Thomas Pabst; Johan Maertens; H Berna Beverloo; Marinus van Marwijk Kooy; Pierre W Wijermans; Bart J Biemond; Edo Vellenga; Leo F Verdonck; Gert J Ossenkoppele; Bob Löwenberg Journal: J Clin Oncol Date: 2012-05-07 Impact factor: 44.544
Authors: Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele Journal: Nat Rev Clin Oncol Date: 2012-09-04 Impact factor: 66.675
Authors: Martin Bornhäuser; Joachim Kienast; Rudolf Trenschel; Andreas Burchert; Ute Hegenbart; Michael Stadler; Herrad Baurmann; Kerstin Schäfer-Eckart; Ernst Holler; Nicolaus Kröger; Christoph Schmid; Herrmann Einsele; Michael G Kiehl; Wolfgang Hiddemann; Rainer Schwerdtfeger; Stefanie Buchholz; Peter Dreger; Andreas Neubauer; Wolfgang E Berdel; Gerhard Ehninger; Dietrich W Beelen; Johannes Schetelig; Matthias Stelljes Journal: Lancet Oncol Date: 2012-09-07 Impact factor: 41.316
Authors: O Visser; A Trama; M Maynadié; C Stiller; R Marcos-Gragera; R De Angelis; S Mallone; C Tereanu; C Allemani; U Ricardi; H C Schouten Journal: Eur J Cancer Date: 2012-07-04 Impact factor: 9.162
Authors: H J Khoury; M Kukreja; J M Goldman; T Wang; J Halter; M Arora; V Gupta; D A Rizzieri; B George; A Keating; R P Gale; D I Marks; P L McCarthy; A Woolfrey; J Szer; S A Giralt; R T Maziarz; J Cortes; M M Horowitz; S J Lee Journal: Bone Marrow Transplant Date: 2011-10-10 Impact factor: 5.483
Authors: Betina Yanez; Chloe J Taub; Margaret Waltz; Alma Diaz; Diana Buitrago; Katrin Bovbjerg; Anthony Chicaiza; Rebecca Thompson; Scott Rowley; Jonathan Moreira; Kristi D Graves; Christine Rini Journal: Int J Behav Med Date: 2022-10-20
Authors: Mira Parisek; Julika Loss; Ernst Holler; Anna Barata; Daniela Weber; Matthias Edinger; Daniel Wolff; Helene Schoemans; Anne Herrmann Journal: Front Public Health Date: 2021-07-01